Gout was associated with increased risks for CV events and all-cause mortality, even after adjusting for long-term CV risk profiles and their changes.

It’s the first study to show a PCSK9 inhibitor can reduce major events in high-risk patients who haven’t yet had one.

Merck’s Enlicitide Decanoate, an Investigational Oral PCSK9 Inhibitor, Significantly Reduced LDL-C in Phase 3 CORALreef ...

Find out more about What content works best on LinkedIn in 2025? A practical guide for professionals, don't miss it.

According to analysts, Tata Motors' demerger will pave the way for both businesses to pursue targeted strategies and capital ...

Best Data Removal Services Guide. Use a data removal service and data removal tool to remove your data from data broker sites ...

The small-profile device expands to capture clots like large-bore systems while offering good reduction in RV/LV ratio at 48 ...

In a phase 1 trial, a gene-editing therapy that targets ANGPTL3 was associated with few serious adverse events and at higher ...

The head of the U.S. Food and Drug Administration’s drug division, Dr. George F. Tidmarsh, resigned on November 2, 2025, one ...

The FDA has approved Rybelsus® to reduce the risk of MACE in adults with T2DM who are at high risk for these events.

U.S. Marines with Weapons Company, 1st Battalion, 3rd Marine Regiment, disembark an MV-22 Osprey during a tactical recovery ...

D emocrats were bound to have a good election night. The prevailing question on November 4th was more a matter of degree: ...